SCHEMBL6096550

SCHEMBL6096550

COC1=C(OC)C(=O)C(Cc2ccc(O)c(C(=O)Nc3ccc(C(C)=O)cc3)c2)=C(C)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 3/20 0.43
F2 P00734 2/20 0.43
F10 P00742 2/20 0.43
PLAT P00750 2/20 0.43
MAPT P10636 4/20 0.41
RAB9A P51151 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 4/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 1/20 0.40
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
KLKB1 P03952 3/20 0.40
PLG P00747 2/20 0.40
KLK1 P06870 2/20 0.40
KLK6 Q92876 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096291 0.92 F2 (0.43) PLAUF2F10PLATMAPT
SCHEMBL6093802 0.90 NPC1 (0.52) PLAUF2F10PLATMAPT
SCHEMBL6096470 0.89 SMN1; SMN2 (0.49) MAPTRAB9ASMN1; SMN2NPC1MEN1
SCHEMBL6097408 0.89 P2RX1 (0.51) MAPTMEN1KMT2AKLKB1ALOX15
SCHEMBL6097223 0.89 P2RX1 (0.47) PLAUF2F10PLATMAPT
SCHEMBL6097073 0.89 KLKB1 (0.43) PLAUF2F10PLATMAPT
SCHEMBL6096859 0.88 STAT3 (0.45) PLAUF2F10PLATMAPT
SCHEMBL6094337 0.87 CCR5 (0.43) MAPTRAB9ASMN1; SMN2NPC1MEN1
SCHEMBL6095585 0.87 KCNMA1 (0.47) MAPTRAB9ASMN1; SMN2NPC1MEN1
SCHEMBL6096672 0.86 TMPRSS4 (0.50) PLAUF2F10PLATMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064124-B2 NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-06-20 US claimed
US-7064124-B2 NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-06-20 US disclosed
US-20040122244-A1 Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2004-06-24 US disclosed
EP-1314712-A1 NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT Daiichi Suntory Pharma Co., Ltd. (JP) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122244-A1 Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient NFKBIA, NFKB1, IKBKB PLAU 4096/4885F2 3556/4885F10 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.